Nuvaxovid

Overview

COVID-19 vaccine

vaccine

• non-live vaccine

Avoid/Use Alternative

• interferon gamma 1b
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

interferon gamma 1b

1 interaction

Avoid/Use Alternative

COVID-19 vaccine + interferon gamma 1b

avoid combo: combo may result in amplified immune response (immunomodulatory effects)

Monitor/Modify Tx

• abatacept
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

abatacept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + abatacept

if possible, vaccinate at least 2wk before or 3mo after abatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abemaciclib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

abemaciclib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + abemaciclib

if possible, vaccinate at least 2wk before or 3mo after abemaciclib use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abrocitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

abrocitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + abrocitinib

if possible, vaccinate at least 2wk before or 3mo after abrocitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• acalabrutinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

acalabrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + acalabrutinib

if possible, vaccinate at least 2wk before or 3mo after acalabrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• adalimumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

adalimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + adalimumab

if possible, vaccinate at least 2wk before or 3mo after adalimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ado-trastuzumab emtansine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ado-trastuzumab emtansine

if possible, vaccinate at least 2wk before or 3mo after ado-trastuzumab emtansine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• afamitresgene autoleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + afamitresgene autoleucel

if possible, vaccinate at least 2wk before or 3mo after afamitresgene autoleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• aldesleukin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

aldesleukin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + aldesleukin

if possible, vaccinate at least 2wk before or 3mo after aldesleukin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• alemtuzumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

alemtuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + alemtuzumab

if possible, vaccinate at least 4wk before or 3-6mo after alemtuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• amivantamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

amivantamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + amivantamab

if possible, vaccinate at least 2wk before or 3mo after amivantamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anakinra
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

anakinra

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + anakinra

if possible, vaccinate at least 2wk before or 3mo after anakinra tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anifrolumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

anifrolumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + anifrolumab

if possible, vaccinate at least 2wk before or 3mo after anifrolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + anti-thymocyte globulin

if possible, vaccinate at least 4wk before or 3-6mo after anti-thymocyte globulin use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• asciminib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

asciminib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + asciminib

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atacicept
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

atacicept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + atacicept

if possible, vaccinate at least 4wk before or 3-6mo after atacicept use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atezolizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

atezolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + atezolizumab

if possible, vaccinate at least 2wk before or 3mo after atezolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atidarsagene autotemcel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + atidarsagene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• avelumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

avelumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + avelumab

if possible, vaccinate at least 2wk before or 3mo after avelumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• avutometinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

avutometinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + avutometinib

if possible, vaccinate at least 2wk before or 3mo after avutometinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• axicabtagene ciloleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + axicabtagene ciloleucel

if possible, vaccinate at least 4wk before or 3-6mo after axicabtagene ciloleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azacitidine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

azacitidine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + azacitidine

if possible, vaccinate at least 2wk before or 3mo after azacitidine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azathioprine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

azathioprine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + azathioprine

if possible, vaccinate at least 2wk before or 3mo after azathioprine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• baricitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

baricitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + baricitinib

if possible, vaccinate at least 2wk before or 3mo after baricitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• basiliximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

basiliximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + basiliximab

if possible, vaccinate at least 2wk before or 3mo after basiliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belantamab mafodotin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belantamab mafodotin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belantamab mafodotin

if possible, vaccinate at least 2wk before starting belantamab mafodotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belatacept
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belatacept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belatacept

if possible, vaccinate at least 2wk before or 3mo after belatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belimumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belimumab

if possible, vaccinate at least 4wk before or 3-6mo after belimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belinostat
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belinostat

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belinostat

if possible, vaccinate at least 2wk before or 3mo after belinostat tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belzutifan
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belzutifan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belzutifan

if possible, vaccinate at least 2wk before or 3mo after belzutifan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bendamustine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bendamustine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bendamustine

if possible, vaccinate at least 2wk before or 3mo after bendamustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• betamethasone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

betamethasone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + betamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• bevacizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bevacizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bevacizumab

if possible, vaccinate at least 2wk before or 3mo after bevacizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bimekizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bimekizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bimekizumab

if possible, vaccinate at least 2wk before or 3mo after bimekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• blinatumomab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

blinatumomab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + blinatumomab

if possible, vaccinate at least 4wk before or 3-6mo after blinatumomab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bortezomib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bortezomib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bortezomib

if possible, vaccinate at least 2wk before or 3mo after bortezomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brentuximab vedotin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + brentuximab vedotin

if possible, vaccinate at least 4wk before or 3-6mo after brentuximab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brexucabtagene autoleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + brexucabtagene autoleucel

if possible, vaccinate at least 4wk before or 3-6mo after brexucabtagene autoleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brodalumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

brodalumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + brodalumab

if possible, vaccinate at least 2wk before or 3mo after brodalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

budesonide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + budesonide

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide rectal
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

budesonide rectal

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + budesonide rectal

consider vaccinating at least 2wk before budesonide rectal use; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• busulfan
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

busulfan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + busulfan

if possible, vaccinate at least 2wk before or 3mo after busulfan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cabazitaxel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cabazitaxel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cabazitaxel

if possible, vaccinate at least 2wk before or 3mo after cabazitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• canakinumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

canakinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + canakinumab

if possible, vaccinate at least 2wk before or 3mo after canakinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capecitabine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

capecitabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + capecitabine

if possible, vaccinate at least 2wk before or 3mo after capecitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capmatinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

capmatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + capmatinib

if possible, vaccinate at least 2wk before or 3mo after capmatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carboplatin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

carboplatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + carboplatin

if possible, vaccinate at least 2wk before or 3mo after carboplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carfilzomib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

carfilzomib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + carfilzomib

if possible, vaccinate at least 2wk before or 3mo after carfilzomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carmustine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

carmustine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + carmustine

if possible, vaccinate at least 2wk before or 3mo after carmustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cemiplimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cemiplimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cemiplimab

if possible, vaccinate at least 2wk before or 3mo after cemiplimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• certolizumab pegol
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

certolizumab pegol

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + certolizumab pegol

if possible, vaccinate at least 2wk before or 3mo after certolizumab pegol tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cetuximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cetuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cetuximab

if possible, vaccinate at least 2wk before or 3mo after cetuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorambucil
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

chlorambucil

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + chlorambucil

if possible, vaccinate at least 2wk before or 3mo after chlorambucil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ciltacabtagene autoleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ciltacabtagene autoleucel

if possible, vaccinate at least 4wk before or 3-6mo after ciltacabtagene autoleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cisplatin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cisplatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cisplatin

if possible, vaccinate at least 2wk before or 3mo after cisplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine injection
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cladribine injection

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cladribine injection

if possible, vaccinate at least 2wk before or 3mo after cladribine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine oral
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cladribine oral

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cladribine oral

if possible, vaccinate at least 2wk before or 3mo after cladribine use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• clofarabine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

clofarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + clofarabine

if possible, vaccinate at least 2wk before or 3mo after clofarabine use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• copanlisib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

copanlisib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + copanlisib

if possible, vaccinate at least 2wk before or 3mo after copanlisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• corticotropin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

corticotropin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + corticotropin

if possible, vaccinate at least 2wk before or 3mo after corticotropin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cortisone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cortisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• cosibelimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cosibelimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cosibelimab

if possible, vaccinate at least 2wk before or 3mo after cosibelimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cyclophosphamide

if possible, vaccinate at least 2wk before or 3mo after cyclophosphamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclosporine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cyclosporine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cyclosporine

if possible, vaccinate at least 2wk before or 3mo after cyclosporine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cytarabine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cytarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cytarabine

if possible, vaccinate at least 2wk before or 3mo after cytarabine use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dacarbazine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dacarbazine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dacarbazine

if possible, vaccinate at least 2wk before or 3mo after dacarbazine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dactinomycin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dactinomycin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dactinomycin

if possible, vaccinate at least 2wk before or 3mo after dactinomycin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daratumumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

daratumumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + daratumumab

if possible, vaccinate at least 4wk before or 3-6mo after daratumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dasatinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dasatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dasatinib

if possible, vaccinate at least 2wk before or 3mo after dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daunorubicin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

daunorubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + daunorubicin

if possible, vaccinate at least 2wk before or 3mo after daunorubicin use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• decitabine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

decitabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + decitabine

if possible, vaccinate at least 2wk before or 3mo after decitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• defactinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

defactinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + defactinib

if possible, vaccinate at least 2wk before or 3mo after defactinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deflazacort
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

deflazacort

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + deflazacort

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• delgocitinib topical
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

delgocitinib topical

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + delgocitinib topical

if possible, vaccinate at least 2wk before or 3mo after delgocitinib topical tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deucravacitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

deucravacitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + deucravacitinib

if possible, vaccinate at least 2wk before or 3mo after deucravacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deuruxolitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + deuruxolitinib

if possible, vaccinate at least 2wk before or 3mo after deuruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dexamethasone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dexamethasone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dexamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• dimethyl fumarate
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dimethyl fumarate

if possible, vaccinate at least 2wk before or 3mo after dimethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dinutuximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dinutuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dinutuximab

if possible, vaccinate at least 2wk before or 3mo after dinutuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diroximel fumarate
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + diroximel fumarate

if possible, vaccinate at least 2wk before or 3mo after diroximel fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• docetaxel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

docetaxel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + docetaxel

if possible, vaccinate at least 2wk before or 3mo after docetaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dordaviprone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dordaviprone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dordaviprone

if possible, vaccinate at least 2wk before or 3mo after dordaviprone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dostarlimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dostarlimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dostarlimab

if possible, vaccinate at least 2wk before or 3mo after dostarlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• doxorubicin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

doxorubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + doxorubicin

if possible, vaccinate at least 2wk before or 3mo after doxorubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dupilumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dupilumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dupilumab

if possible, vaccinate at least 2wk before or 3mo after dupilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• durvalumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

durvalumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + durvalumab

if possible, vaccinate at least 2wk before or 3mo after durvalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• duvelisib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

duvelisib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + duvelisib

if possible, vaccinate at least 2wk before or 3mo after duvelisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• efgartigimod alfa
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

efgartigimod alfa

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + efgartigimod alfa

if possible, vaccinate at least 2wk before or 3mo after efgartigimod alfa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elivaldogene autotemcel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + elivaldogene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• elotuzumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

elotuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + elotuzumab

if possible, vaccinate at least 2wk before or 3mo after elotuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elranatamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

elranatamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + elranatamab

if possible, vaccinate at least 4wk before or 3-6mo after elranatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• emapalumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

emapalumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + emapalumab

if possible, vaccinate at least 2wk before or 3mo after emapalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epcoritamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

epcoritamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + epcoritamab

if possible, vaccinate at least 4wk before or 3-6mo after epcoritamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epirubicin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

epirubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + epirubicin

if possible, vaccinate at least 2wk before or 3mo after epirubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• erdafitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

erdafitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + erdafitinib

if possible, vaccinate at least 2wk before starting erdafitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• eribulin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

eribulin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + eribulin

if possible, vaccinate at least 2wk before or 3mo after eribulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etanercept
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

etanercept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + etanercept

if possible, vaccinate at least 2wk before or 3mo after etanercept use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etoposide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

etoposide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + etoposide

if possible, vaccinate at least 2wk before or 3mo after etoposide use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etrasimod
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

etrasimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + etrasimod

if possible, vaccinate at least 2wk before or 3mo after etrasimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etuvetidigene autotemcel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + etuvetidigene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• everolimus
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

everolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + everolimus

if possible, vaccinate at least 2wk before or 3mo after everolimus use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fam-trastuzumab deruxtecan
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fam-trastuzumab deruxtecan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fam-trastuzumab deruxtecan

if possible, vaccinate at least 2wk before or 3mo after fam-trastuzumab deruxtecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fingolimod
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fingolimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fingolimod

if possible, vaccinate at least 2wk before or 3mo after fingolimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• floxuridine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

floxuridine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + floxuridine

if possible, vaccinate at least 2wk before or 3mo after floxuridine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludarabine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fludarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fludarabine

if possible, vaccinate at least 2wk before or 3mo after fludarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludrocortisone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fludrocortisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fludrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• fluorouracil
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fluorouracil

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fluorouracil

if possible, vaccinate at least 2wk before or 3mo after fluorouracil use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fruquintinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fruquintinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fruquintinib

if possible, vaccinate at least 2wk before or 3mo after fruquintinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• futibatinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

futibatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + futibatinib

if possible, vaccinate at least 2wk before starting futibatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemcitabine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

gemcitabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + gemcitabine

if possible, vaccinate at least 2wk before or 3mo after gemcitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemtuzumab ozogamicin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + gemtuzumab ozogamicin

if possible, vaccinate at least 4wk before or 3-6mo after gemtuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• glofitamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

glofitamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + glofitamab

if possible, vaccinate at least 4wk before or 3-6mo after glofitamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• golimumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

golimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + golimumab

if possible, vaccinate at least 2wk before or 3mo after golimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• guselkumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

guselkumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + guselkumab

if possible, vaccinate at least 2wk before or 3mo after guselkumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydrocortisone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

hydrocortisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + hydrocortisone

if possible, vaccinate at least 2wk before long-term (>2wk) high-dose systemic steroid use; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydroxyurea
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

hydroxyurea

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + hydroxyurea

if possible, vaccinate at least 2wk before or 3mo after hydroxyurea tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• iberdomide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

iberdomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + iberdomide

if possible, vaccinate at least 2wk before or 3mo after iberdomide use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibritumomab tiuxetan
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ibritumomab tiuxetan

if possible, vaccinate at least 4wk before or 3-6mo after ibritumomab tiuxetan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibrutinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ibrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ibrutinib

if possible, vaccinate at least 2wk before or 3mo after ibrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• icotrokinra
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

icotrokinra

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + icotrokinra

if possible, vaccinate at least 2wk before or 3mo after icotrokinra use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idarubicin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

idarubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + idarubicin

if possible, vaccinate at least 2wk before or 3mo after idarubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idecabtagene vicleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + idecabtagene vicleucel

if possible, vaccinate at least 4wk before or 3-6mo after idecabtagene vicleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idelalisib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

idelalisib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + idelalisib

if possible, vaccinate at least 2wk before or 3mo after idelalisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ifosfamide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ifosfamide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ifosfamide

if possible, vaccinate at least 2wk before or 3mo after ifosfamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• imatinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

imatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + imatinib

if possible, vaccinate at least 2wk before or 3mo after imatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inebilizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

inebilizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + inebilizumab

if possible, vaccinate at least 4wk before or 3-6mo after inebilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• infliximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

infliximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + infliximab

if possible, vaccinate at least 2wk before or 3mo after infliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inotuzumab ozogamicin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + inotuzumab ozogamicin

if possible, vaccinate at least 4wk before or 3-6mo after inotuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ipilimumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ipilimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ipilimumab

if possible, vaccinate at least 2wk before or 3mo after ipilimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• irinotecan
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

irinotecan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + irinotecan

if possible, vaccinate at least 2wk before or 3mo after irinotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• isatuximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

isatuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + isatuximab

if possible, vaccinate at least 4wk before or 3-6mo after isatuximab use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixabepilone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ixabepilone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ixabepilone

if possible, vaccinate at least 2wk before or 3mo after ixabepilone use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixekizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ixekizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ixekizumab

if possible, vaccinate at least 2wk before or 3mo after ixekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lazertinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lazertinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lazertinib

if possible, vaccinate at least 2wk before or 3mo after lazertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lebrikizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lebrikizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lebrikizumab

if possible, vaccinate at least 2wk before or 3mo after lebrikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• leflunomide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

leflunomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + leflunomide

if possible, vaccinate at least 2wk before or 3mo after leflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lenalidomide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lenalidomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lenalidomide

if possible, vaccinate at least 2wk before or 3mo after lenalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lifileucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lifileucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lifileucel

if possible, vaccinate at least 2wk before or 3mo after lifileucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• linvoseltamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

linvoseltamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + linvoseltamab

if possible, vaccinate at least 4wk before or 3-6mo after linvoseltamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lisocabtagene maraleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lisocabtagene maraleucel

if possible, vaccinate at least 4wk before or 3-6mo after lisocabtagene maraleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lomustine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lomustine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lomustine

if possible, vaccinate at least 2wk before or 3mo after lomustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• loncastuximab tesirine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + loncastuximab tesirine

if possible, vaccinate at least 4wk before or 3-6mo after loncastuximab tesirine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lurbinectedin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lurbinectedin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lurbinectedin

if possible, vaccinate at least 2wk before or 3mo after lurbinectedin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lymphocyte immune globulin, anti-thymocyte globulin

if possible, vaccinate at least 4wk before or 3-6mo after anti-thymocyte globulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• margetuximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

margetuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + margetuximab

if possible, vaccinate at least 2wk before or 3mo after margetuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• marnetegragene autotemcel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

marnetegragene autotemcel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + marnetegragene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• melphalan
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

melphalan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + melphalan

if possible, vaccinate at least 2wk before or 3mo after melphalan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mercaptopurine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mercaptopurine

if possible, vaccinate at least 2wk before or 3mo after mercaptopurine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methotrexate
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

methotrexate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + methotrexate

if possible, vaccinate at least 2wk before or 3mo after methotrexate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methylprednisolone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

methylprednisolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + methylprednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• midostaurin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

midostaurin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + midostaurin

if possible, vaccinate at least 2wk before or 3mo after midostaurin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mirikizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mirikizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mirikizumab

if possible, vaccinate at least 2wk before or 3mo after mirikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitomycin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mitomycin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mitomycin

if possible, vaccinate at least 2wk before or 3mo after mitomycin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitoxantrone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mitoxantrone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mitoxantrone

if possible, vaccinate at least 2wk before or 3mo after mitoxantrone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mogamulizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mogamulizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mogamulizumab

if possible, vaccinate at least 2wk before or 3mo after mogamulizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• momelotinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

momelotinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + momelotinib

if possible, vaccinate at least 2wk before or 3mo after momelotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• monomethyl fumarate
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + monomethyl fumarate

if possible, vaccinate at least 2wk before or 3mo after monomethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mosunetuzumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mosunetuzumab

if possible, vaccinate at least 4wk before or 3-6mo after mosunetuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolate mofetil
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mycophenolate mofetil

if possible, vaccinate at least 2wk before or 3mo after mycophenolate mofetil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolic acid
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mycophenolic acid

if possible, vaccinate at least 2wk before or 3mo after mycophenolic acid tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• natalizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

natalizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + natalizumab

if possible, vaccinate at least 2wk before or 3mo after natalizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nelarabine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nelarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nelarabine

if possible, vaccinate at least 2wk before or 3mo after nelarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nemolizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nemolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nemolizumab

if possible, vaccinate at least 2wk before or 3mo after nemolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nilotinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nilotinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nilotinib

if possible, vaccinate at least 2wk before or 3mo after nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nipocalimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nipocalimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nipocalimab

if possible, vaccinate at least 2wk before or 3mo after nipocalimab use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nivolumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nivolumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nivolumab

if possible, vaccinate at least 2wk before or 3mo after nivolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nogapendekin alfa inbakicept intravesical
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nogapendekin alfa inbakicept intravesical

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nogapendekin alfa inbakicept intravesical

if possible, vaccinate at least 2wk before or 3mo after nogapendekin alfa inbakicept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obecabtagene autoleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + obecabtagene autoleucel

if possible, vaccinate at least 4wk before or 3-6mo after obecabtagene autoleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obinutuzumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

obinutuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + obinutuzumab

if possible, vaccinate at least 4wk before or 3-6mo after obinutuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ocrelizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ocrelizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ocrelizumab

if possible, vaccinate at least 4wk before or 3-6mo after ocrelizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ofatumumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ofatumumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ofatumumab

if possible, vaccinate at least 4wk before or 3-6mo after ofatumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• olaparib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

olaparib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + olaparib

if possible, vaccinate at least 2wk before or 3mo after olaparib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• oxaliplatin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

oxaliplatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + oxaliplatin

if possible, vaccinate at least 2wk before or 3mo after oxaliplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ozanimod
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ozanimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ozanimod

if possible, vaccinate at least 2wk before or 3mo after ozanimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• paclitaxel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

paclitaxel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + paclitaxel

if possible, vaccinate at least 2wk before or 3mo after paclitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pacritinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pacritinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pacritinib

if possible, vaccinate at least 2wk before or 3mo after pacritinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• palbociclib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

palbociclib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + palbociclib

if possible, vaccinate at least 2wk before or 3mo after palbociclib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• panitumumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

panitumumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + panitumumab

if possible, vaccinate at least 2wk before or 3mo after panitumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pariglasgene brecaparvovec
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pariglasgene brecaparvovec

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pariglasgene brecaparvovec

if possible, vaccinate at least 4wk before or 3 mo after pariglasgene brecaparvovec use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• peginterferon alfa 2a
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + peginterferon alfa 2a

if possible, vaccinate at least 2wk before or 3mo after peginterferon alfa 2a tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pembrolizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pembrolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pembrolizumab

if possible, vaccinate at least 2wk before or 3mo after pembrolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pemetrexed
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pemetrexed

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pemetrexed

if possible, vaccinate at least 2wk before or 3mo after pemetrexed; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pemivibart
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pemivibart

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pemivibart

admin. pemivibart at least 2wk after vaccine: combo may result in inadequate vaccine response (antagonistic effects)

• penpulimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

penpulimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + penpulimab

if possible, vaccinate at least 2wk before or 3mo after penpulimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pentostatin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pentostatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pentostatin

if possible, vaccinate at least 2wk before or 3mo after pentostatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pertuzumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pertuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pertuzumab

if possible, vaccinate at least 2wk before or 3mo after pertuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pirtobrutinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pirtobrutinib

if possible, vaccinate at least 2wk before or 3mo after pirtobrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• polatuzumab vedotin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + polatuzumab vedotin

if possible, vaccinate at least 4wk before or 3-6mo after polatuzumab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pomalidomide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pomalidomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pomalidomide

if possible, vaccinate at least 2wk before or 3mo after pomalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponatinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ponatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ponatinib

if possible, vaccinate at least 2wk before or 3mo after ponatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponesimod
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ponesimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ponesimod

if possible, vaccinate at least 2wk before or 3mo after ponesimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pralatrexate
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pralatrexate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pralatrexate

if possible, vaccinate at least 2wk before or 3mo after pralatrexate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisolone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

prednisolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + prednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

prednisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + prednisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• procarbazine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

procarbazine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + procarbazine

if possible, vaccinate at least 2wk before or 3mo after procarbazine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• quizartinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

quizartinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + quizartinib

if possible, vaccinate at least 2wk before or 3mo after quizartinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• regorafenib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

regorafenib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + regorafenib

if possible, vaccinate at least 2wk before or 3mo after regorafenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• relacorilant
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

relacorilant

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + relacorilant

if possible, vaccinate at least 2wk before or 3mo after relacorilant use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• relatlimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

relatlimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + relatlimab

if possible, vaccinate at least 2wk before or 3mo after relatlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• retifanlimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

retifanlimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + retifanlimab

if possible, vaccinate at least 2wk before or 3mo after retifanlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• revumenib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

revumenib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + revumenib

if possible, vaccinate at least 2wk before starting revumenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilonacept
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rilonacept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rilonacept

if possible, vaccinate at least 2wk before or 3mo after rilonacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilzabrutinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rilzabrutinib

if possible, vaccinate at least 4wk before or 3-6mo after rilzabrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ripretinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ripretinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ripretinib

if possible, vaccinate at least 2wk before or 3mo after ripretinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• risankizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

risankizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + risankizumab

if possible, vaccinate at least 2wk before or 3mo after risankizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ritlecitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ritlecitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ritlecitinib

if possible, vaccinate at least 2wk before or 3mo after ritlecitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rituximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rituximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rituximab

if possible, vaccinate at least 4wk before or 3-6mo after rituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• romidepsin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

romidepsin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + romidepsin

if possible, vaccinate at least 2wk before or 3mo after romidepsin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ropeginterferon alfa-2b
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ropeginterferon alfa-2b

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ropeginterferon alfa-2b

if possible, vaccinate at least 2wk before or 3mo after ropeginterferon alfa-2b tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rozanolixizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rozanolixizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rozanolixizumab

if possible, vaccinate at least 2wk before or 3mo after rozanolixizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rucaparib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rucaparib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rucaparib

if possible, vaccinate at least 2wk before or 3mo after rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ruxolitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ruxolitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ruxolitinib

if possible, vaccinate at least 2wk before or 3mo after ruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sarilumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sarilumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sarilumab

if possible, vaccinate at least 2wk before or 3mo after sarilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• satralizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

satralizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + satralizumab

if possible, vaccinate at least 2wk before or 3mo after satralizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• secukinumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

secukinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + secukinumab

if possible, vaccinate at least 2wk before or 3mo after secukinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selinexor
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

selinexor

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + selinexor

if possible, vaccinate at least 2wk before or 3mo after selinexor tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selumetinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

selumetinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + selumetinib

if possible, vaccinate at least 2wk before or 3mo after selumetinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sevabertinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sevabertinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sevabertinib

if possible, vaccinate at least 2wk before or 3mo after sevabertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sibeprenlimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sibeprenlimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sibeprenlimab

if possible, vaccinate at least 2wk before or 3mo after starting sibeprenlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siltuximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

siltuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + siltuximab

if possible, vaccinate at least 2wk before or 3mo after siltuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siponimod
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

siponimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + siponimod

if possible, vaccinate at least 2wk before or 3mo after siponimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sipuleucel-T
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sipuleucel-T

if possible, vaccinate at least 2wk before or 3mo after sipuleucel-T tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sirolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sirolimus

if possible, vaccinate at least 2wk before or 3mo after sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus albumin-bound
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sirolimus albumin-bound

if possible, vaccinate at least 2wk before or 3mo after sirolimus albumin-bound tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus topical
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sirolimus topical

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sirolimus topical

if possible, vaccinate at least 2wk before or 3mo after sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• smallpox vaccine, live
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

smallpox vaccine, live

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + smallpox vaccine, live

if possible, hold mRNA COVID-19 vaccine or protein subunit COVID-19 vaccine for at least 4wk after smallpox vaccine: combo may incr. risk of myocarditis (possible additive effects)

• smallpox/mpox vaccine, live
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

smallpox/ mpox vaccine, live

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + smallpox/ mpox vaccine, live

if possible, hold mRNA COVID-19 vaccine or protein subunit COVID-19 vaccine for at least 4wk after smallpox/mpox vaccine: combo may incr. risk of myocarditis (possible additive effects)

• sonrotoclax
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sonrotoclax

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sonrotoclax

if possible, vaccinate at least 4wk before or 3-6mo after sonrotoclax use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sorafenib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sorafenib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sorafenib

if possible, vaccinate at least 2wk before or 3mo after sorafenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• spesolimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

spesolimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + spesolimab

if possible, vaccinate at least 2wk before or 3mo after spesolimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sunitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sunitinib

if possible, vaccinate at least 2wk before or 3mo after sunitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunvozertinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sunvozertinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sunvozertinib

if possible, vaccinate at least 2wk before or 3mo after sunvozertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tacrolimus
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tacrolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tacrolimus

if possible, vaccinate at least 2wk before or 3mo after tacrolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tafasitamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tafasitamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tafasitamab

if possible, vaccinate at least 4wk before or 3-6mo after tafasitamab use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• taletrectinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

taletrectinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + taletrectinib

if possible, vaccinate at least 2wk before or 3mo after taletrectinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• talquetamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

talquetamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + talquetamab

if possible, vaccinate at least 4wk before or 3-6mo after talquetamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tarlatamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tarlatamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tarlatamab

if possible, vaccinate at least 2wk before or 3mo after tarlatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teclistamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

teclistamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + teclistamab

if possible, vaccinate at least 4wk before or 3-6mo after teclistamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• telisotuzumab vedotin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

telisotuzumab vedotin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + telisotuzumab vedotin

if possible, vaccinate at least 2wk before or 3mo after telisotuzumab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temozolomide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

temozolomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + temozolomide

if possible, vaccinate at least 2wk before or 3mo after temozolomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temsirolimus
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

temsirolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + temsirolimus

if possible, vaccinate at least 2wk before or 3mo after temsirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teplizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

teplizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + teplizumab

vaccinate at least 2wk before or 6wk after teplizumab tx; otherwise, consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• teriflunomide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

teriflunomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + teriflunomide

if possible, vaccinate at least 2wk before or 3mo after teriflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thalidomide
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

thalidomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + thalidomide

if possible, vaccinate at least 2wk before or 3mo after thalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thioguanine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

thioguanine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + thioguanine

if possible, vaccinate at least 2wk before or 3mo after thioguanine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thiotepa
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

thiotepa

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + thiotepa

if possible, vaccinate at least 2wk before or 3mo after thiotepa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tildrakizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tildrakizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tildrakizumab

if possible, vaccinate at least 2wk before or 3mo after tildrakizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tisagenlecleucel
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tisagenlecleucel

if possible, vaccinate at least 4wk before or 3-6mo after tisagenlecleucel use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tislelizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tislelizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tislelizumab

if possible, vaccinate at least 2wk before or 3mo after tislelizumab use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tocilizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tocilizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tocilizumab

if possible, vaccinate at least 2wk before or 3mo after tocilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tofacitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tofacitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tofacitinib

if possible, vaccinate at least 2wk before or 3mo after tofacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• topotecan
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

topotecan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + topotecan

if possible, vaccinate at least 2wk before or 3mo after topotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• toripalimab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

toripalimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + toripalimab

if possible, vaccinate at least 2wk before or 3mo after toripalimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• trabectedin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

trabectedin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + trabectedin

if possible, vaccinate at least 2wk before or 3mo after trabectedin use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tralokinumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tralokinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tralokinumab

if possible, vaccinate at least 2wk before or 3mo after tralokinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• trastuzumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

trastuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + trastuzumab

if possible, vaccinate at least 2wk before or 3mo after trastuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tremelimumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tremelimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tremelimumab

if possible, vaccinate at least 2wk before or 3mo after tremelimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• triamcinolone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

triamcinolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + triamcinolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• ublituximab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ublituximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ublituximab

if possible, vaccinate at least 4wk before or 3-6mo after ublituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• upadacitinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

upadacitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + upadacitinib

if possible, vaccinate at least 2wk before or 3mo after upadacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ustekinumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ustekinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ustekinumab

if possible, vaccinate at least 2wk before or 3mo after ustekinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vamorolone
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vamorolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vamorolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• vandetanib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vandetanib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vandetanib

if possible, vaccinate at least 2wk before or 3mo after vandetanib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vedolizumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vedolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vedolizumab

if possible, vaccinate at least 2wk before or 3mo after vedolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• venetoclax
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

venetoclax

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + venetoclax

if possible, vaccinate at least 4wk before or 3-6mo after venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinblastine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vinblastine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vinblastine

if possible, vaccinate at least 2wk before or 3mo after vinblastine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vincristine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vincristine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vincristine

if possible, vaccinate at least 2wk before or 3mo after vincristine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinorelbine
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vinorelbine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vinorelbine

if possible, vaccinate at least 2wk before or 3mo after vinorelbine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• voclosporin
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

voclosporin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + voclosporin

if possible, vaccinate at least 2wk before or 3mo after voclosporin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanidatamab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

zanidatamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + zanidatamab

if possible, vaccinate at least 2wk before or 3mo after zanidatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanubrutinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

zanubrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + zanubrutinib

if possible, vaccinate at least 2wk before or 3mo after zanubrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zenocutuzumab
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

zenocutuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + zenocutuzumab

if possible, vaccinate at least 2wk before or 3mo after zenocutuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ziftomenib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ziftomenib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ziftomenib

if possible, vaccinate at least 2wk before starting ziftomenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zongertinib
Nuvaxovid (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

zongertinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + zongertinib

if possible, vaccinate at least 2wk before or 3mo after zongertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)